A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection
- Conditions
- Hepatitis B
- Interventions
- Registration Number
- NCT02604199
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Brief Summary
Patients with chronic HBV infection will receive either ARC-520 or placebo in combination with entecavir or tenofovir, and be evaluated for safety and efficacy.
- Detailed Description
This is a multicenter, randomized, double-blind, placebo-controlled, multi-dose study of ARC-520 in combination with entecavir or tenofovir administered to patients with Hepatitis B 'e' Antigen (HBeAg) negative and immune active chronic HBV infection. Eligible patients who have signed an Ethics Committee - approved informed consent, will be enrolled and will receive ARC-520 or placebo in combination with entecavir or tenofovir. The study will enroll up to a total of 60 eligible chronic HBV infected patients. Patients will undergo the following evaluations at regular intervals during the study: medical history, physical examinations, vital sign measurements (blood pressure, heart rate, respiratory rate and temperature), weight, adverse events assessment (AEs), 12-lead electrocardiograms (ECGs), liver fibrosis testing, concomitant medication assessment, blood sample collection for hematology, coagulation,chemistry, lactate, Pharmacokinetic (PK) measures (in a subset of patients), exploratory Pharmacodynamic (PD) measures, urinalysis, HBV serology, Follicle Stimulating Hormone (FSH) testing (post-menopausal females) and pregnancy testing for females of childbearing potential. Clinically significant changes including AEs will be followed until resolution, until the condition stabilizes, until the event is otherwise explained, or until the patient is lost to follow-up. For each patient, the duration of the study is approximately 33 weeks from screening to the Day 169 follow-up visit. For patients enrolling into a planned extension study, the total duration of this study is approximately 25 weeks from screening to Day 113 end of study visit.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 58
- Male or female, 18 to 75 years of age
- Written informed consent
- No clinically significant abnormalities at screening/pre-dose 12-lead ECG assessment
- No new abnormal finding of clinical relevance at the screening evaluation.
- Diagnosis of HBeAg negative, immune active, chronic HBV infection
- > 2 months of continuous treatment with daily, oral entecavir or tenofovir
- Willingness to continue taking entecavir or tenofovir throughout the study.
- Must use 2 effective methods of contraception (double barrier contraception or hormonal contraceptive along with a barrier contraceptive) (both male and female partners)
- Pregnant or lactating
- Acute signs of hepatitis/other infection within 4 weeks of screening
- Antiviral therapy other than entecavir or tenofovir within 3 months of screening
- Prior treatment with interferon in the last 3 years.
- Use within the last 6 months or anticipated requirement for anticoagulants, corticosteroids, immunomodulators, or immunosuppressants.
- Use of prescription medication within 14 days prior to treatment administration except: topical products without systemic absorption, statins (except rosuvastatin), hypertension medications, or hormonal contraceptives.
- Depot injection or implant of any drug within 3 months prior to treatment administration, except injectable/implantable birth control.
- Diagnosis of diabetes mellitus.
- History of autoimmune disease especially autoimmune hepatitis.
- Human immunodeficiency virus (HIV) infection.
- Sero-positive for Hepatitis C Virus (HCV), and/or a history of delta virus hepatitis.
- Hypertension defined as blood pressure > 150/100 mmHg
- History of cardiac rhythm disturbances
- Family history or congenital long QT syndrome, Brugada syndrome or unexplained sudden cardiac death
- Symptomatic heart failure, unstable angina, myocardial infarction, severe cardiovascular disease within 6 months prior to study entry.
- History of malignancy except for adequately treated basal cell carcinoma, squamous cell skin cancer, superficial bladder tumors, or in situ cervical cancer.
- Has had a major surgery within 3 months of screening.
- History of alcohol and/or drug abuse < 12 months from screening.
- Regular uses of alcohol within 6 months prior to screening (ie, more than 14 units of alcohol per week).
- Evidence of severe systemic acute inflammation, sepsis, or hemolysis.
- Diagnosed with a significant psychiatric disorder.
- Use of recreational drugs, such as marijuana, within 3 months prior to screening
- Use of drugs such as cocaine, phencyclidine (PCP), and methamphetamines, within 1 year prior to screening.
- History of allergy to bee sting.
- Use of investigational agents or devices within 30 days prior to planned study dosing or current participation in an investigational study.
- Clinically significant history or presence of any gastrointestinal pathology, unresolved gastrointestinal symptoms, liver or kidney disease.
- Presence of cholangitis, cholecystitis, cholestasis, or duct obstruction.
- Clinically significant history or presence of poorly controlled/uncontrolled systemic disease.
- History of fever within 2 weeks of screening.
- Immunized with a live attenuated vaccine within 7 days prior to dosing or planned vaccination (excluding flu vaccine by injection).
- Presence of any medical or psychiatric condition or social situation that impacts compliance or results in additional safety risk.
- Participated in excessive exercise/physical activity within 7 days of screening or planned during the trial.
- History of coagulopathy/stroke within past 6 months, and/or concurrent anticoagulant medication(s).
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description PBO High Dose tenofovir 0.9% normal saline, once every 4 weeks for 4 doses plus daily oral entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg) throughout the study period ARC-520 Injection 1 mg/kg tenofovir Intravenous ARC-520 at 1.0 mg/kg, once every 4 weeks for 4 doses plus daily oral entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg) throughout the study period PBO Low Dose placebo 0.9% normal saline, once every 4 weeks for 4 doses plus daily oral entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg) throughout the study period PBO Low Dose antihistamine 0.9% normal saline, once every 4 weeks for 4 doses plus daily oral entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg) throughout the study period PBO High Dose placebo 0.9% normal saline, once every 4 weeks for 4 doses plus daily oral entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg) throughout the study period PBO High Dose antihistamine 0.9% normal saline, once every 4 weeks for 4 doses plus daily oral entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg) throughout the study period ARC-520 Injection 1 mg/kg ARC-520 Injection Intravenous ARC-520 at 1.0 mg/kg, once every 4 weeks for 4 doses plus daily oral entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg) throughout the study period ARC-520 Injection 1 mg/kg antihistamine Intravenous ARC-520 at 1.0 mg/kg, once every 4 weeks for 4 doses plus daily oral entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg) throughout the study period ARC-520 Injection 2 mg/kg ARC-520 Injection Intravenous ARC-520 at 2.0 mg/kg, once every 4 weeks for 4 doses plus daily oral entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg) throughout the study period ARC-520 Injection 2 mg/kg antihistamine Intravenous ARC-520 at 2.0 mg/kg, once every 4 weeks for 4 doses plus daily oral entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg) throughout the study period PBO Low Dose entecavir 0.9% normal saline, once every 4 weeks for 4 doses plus daily oral entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg) throughout the study period PBO Low Dose tenofovir 0.9% normal saline, once every 4 weeks for 4 doses plus daily oral entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg) throughout the study period PBO High Dose entecavir 0.9% normal saline, once every 4 weeks for 4 doses plus daily oral entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg) throughout the study period ARC-520 Injection 1 mg/kg entecavir Intravenous ARC-520 at 1.0 mg/kg, once every 4 weeks for 4 doses plus daily oral entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg) throughout the study period ARC-520 Injection 2 mg/kg entecavir Intravenous ARC-520 at 2.0 mg/kg, once every 4 weeks for 4 doses plus daily oral entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg) throughout the study period ARC-520 Injection 2 mg/kg tenofovir Intravenous ARC-520 at 2.0 mg/kg, once every 4 weeks for 4 doses plus daily oral entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg) throughout the study period
- Primary Outcome Measures
Name Time Method Change From Baseline in Quantitative Hepatitis B Surface Antigen (Log qHBsAg) at Day 113 Baseline, Day 113 Change From Baseline in log qHBsAg at Day 113 in response to multiple doses of ARC-520 versus placebo, using a a mixed effect model for repeated measures (MMRM). Includes parameter baseline as a continuous covariate, and treatment and visit as fixed factors, interaction of treatment and visit, and interaction of parameter baseline and visit.
- Secondary Outcome Measures
Name Time Method Pharmacokinetics of ARC-520: Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours (AUC0-24) Through 48 hours post-dosing on Day 1 and Day 85 Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths and Discontinuations Due to AEs Through Day 169 An AE is any untoward medical occurrence which does not necessarily have a causal relationship with this treatment. An SAE is any AE that: results in death; is life-threatening; requires inpatient hospitalization or prolongation of an existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or is a medically important event or reaction. A treatment emergent AE (TEAE) was defined as an AE that was not present prior to the first study medication administration and started at/after the time of initiation of administration of study medication, or an AE which was present prior to initiation of study medication administration, which increased in severity after study medication administration.
Pharmacokinetics of ARC-520: Terminal Elimination Half-Life (t1/2) Through 48 hours post-dosing on Day 1 and Day 85 Change From Baseline in Quantitative Hepatitis B Surface Antigen (Log qHBsAg) Over Time Baseline, Day 15, 29, 43, 57, 71, 85, 99 Change From Baseline in log qHBsAg at Day 113 in response to multiple doses of ARC-520 versus placebo, using a a mixed effect model for repeated measures (MMRM). Includes parameter baseline as a continuous covariate, and treatment and visit as fixed factors, interaction of treatment and visit, and interaction of parameter baseline and visit.
Pharmacokinetics of ARC-520: Terminal Elimination Rate Constant (Kel) Through 48 hours post-dosing on Day 1 and Day 85 Pharmacokinetics of ARC-520: Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Quantifiable Plasma Concentration (AUClast) Through 48 hours post-dosing on Day 1 and Day 85 Pharmacokinetics of ARC-520: Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUCinf) Through 48 hours post-dosing on Day 1 and Day 85 Pharmacokinetics of ARC-520: Maximum Observed Plasma Concentration (Cmax) Through 48 hours post-dosing on Day 1 and Day 85 Pharmacokinetics of ARC-520: Clearance (CL) Through 48 hours post-dosing on Day 1 and Day 85 Pharmacokinetics of ARC-520: Apparent Volume of Distribution (V) Through 48 hours post-dosing on Day 1 and Day 85
Trial Locations
- Locations (16)
Severance Hospital, Yonsei University College of Medicine
🇰🇷Seoul, Korea, Republic of
Eugastro Gmbh
🇩🇪Leipzig, Germany
University Hospital of Tuebingen
🇩🇪Tuebingen, Germany
Asklepios Klinik St. Georg - Chirurgisch-Traumatologisches Zentrum
🇩🇪Hamburg, Germany
Medizinische Hochschule Hannover
🇩🇪Hannover, Germany
Klinikum Der Ludwig-Maximilian-Universitaet Muenchen
🇩🇪Muenchen, Germany
Universitaetsklinikum Ulm, Klinik fur Innere Medizin I
🇩🇪Ulm, Germany
Universitaetsklinikum Wuerzburg, Medizinische Klinik Und Poliklinik II
🇩🇪Wuerzburg, Germany
Queen Mary Hospital
🇨🇳Hong Kong, China
Klinikum der Johann Wolfgang Goethe Universitaet
🇩🇪Frankfurt, Germany
Prince of Wales Hospital
🇨🇳Hong Kong, China
Universitaetsklinikum Leipzig
🇩🇪Leipzig, Germany
Pusan National University Hospital
🇰🇷Busan, Korea, Republic of
Gachon University Gil Medical Center
🇰🇷Incheon, Korea, Republic of
Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of
Pusan National University Yangsan Hospital
🇰🇷Yangsan-si Gyeongnam, Korea, Republic of